Wednesday, March 31, 2021 - 06:45am In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier analysis, and was well tolerated The companies plan to submit these data to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as soon as possible to request expansion of the Emergency Use Authorization (EUA) and EU Conditional Marketing Authorization for BNT162b2 The companies also provided an update on the Phase 1/2/3 study of BNT162b2 in children aged 6 months to 11 years NEW YORK & MAINZ, Germany-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the Pfizer-BioNTech COVID-19 vaccine BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding...
The Slice News/Report is news entitty owned by Jireh Communications Group and is operated, written and or edited by a member of the working press. The content, whether editorial, exclusive or news headlines is both reliable and credible. The companion radio report airs weekly on AM and FM radio dials nationwide. The Slice News is available at www.theslicenews.com. News from the The Slice is posted on Facebook and other social media outlets to inform the public of current news items.